Influenza A virus diffusion through mucus gel networks. 2022

Logan Kaler, and Ethan Iverson, and Shahed Bader, and Daniel Song, and Margaret A Scull, and Gregg A Duncan
Biophysics Program, University of Maryland, College Park, MD, USA.

Mucus in the lung plays an essential role as a barrier to infection by viral pathogens such as influenza A virus (IAV). Previous work determined mucin-associated sialic acid acts as a decoy receptor for IAV hemagglutinin (HA) binding and the sialic-acid cleaving enzyme, neuraminidase (NA), facilitates virus passage through mucus. However, it has yet to be fully addressed how the physical structure of the mucus gel influences its barrier function and its ability to trap viruses via glycan mediated interactions to prevent infection. To address this, IAV and nanoparticle diffusion in human airway mucus and mucin-based hydrogels is quantified using fluorescence video microscopy. We find the mobility of IAV in mucus is significantly influenced by the mesh structure of the gel and in contrast to prior reports, these effects likely influence virus passage through mucus gels to a greater extent than HA and NA activity. In addition, an analytical approach is developed to estimate the binding affinity of IAV to the mucus meshwork, yielding dissociation constants in the mM range, indicative of weak IAV-mucus binding. Our results provide important insights on how the adhesive and physical barrier properties of mucus influence the dissemination of IAV within the lung microenvironment.

UI MeSH Term Description Entries
D009077 Mucins High molecular weight mucoproteins that protect the surface of EPITHELIAL CELLS by providing a barrier to particulate matter and microorganisms. Membrane-anchored mucins may have additional roles concerned with protein interactions at the cell surface. Mucin
D009093 Mucus The viscous secretion of mucous membranes. It contains mucin, white blood cells, water, inorganic salts, and exfoliated cells.
D009980 Influenza A virus The type species of the genus ALPHAINFLUENZAVIRUS that causes influenza and other diseases in humans and animals. Antigenic variation occurs frequently between strains, allowing classification into subtypes and variants. Transmission is usually by aerosol (human and most non-aquatic hosts) or waterborne (ducks). Infected birds shed the virus in their saliva, nasal secretions, and feces. Alphainfluenzavirus influenzae,Avian Orthomyxovirus Type A,FLUAV,Fowl Plague Virus,Human Influenza A Virus,Influenza Virus Type A,Influenza Viruses Type A,Myxovirus influenzae-A hominis,Myxovirus influenzae-A suis,Myxovirus pestis galli,Orthomyxovirus Type A,Orthomyxovirus Type A, Avian,Orthomyxovirus Type A, Human,Orthomyxovirus Type A, Porcine,Pestis galli Myxovirus,Fowl Plague Viruses,Influenza A viruses,Myxovirus influenzae A hominis,Myxovirus influenzae A suis,Myxovirus, Pestis galli,Myxoviruses, Pestis galli,Pestis galli Myxoviruses,Plague Virus, Fowl,Virus, Fowl Plague
D005782 Gels Colloids with a solid continuous phase and liquid as the dispersed phase; gels may be unstable when, due to temperature or other cause, the solid phase liquefies; the resulting colloid is called a sol.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D019158 N-Acetylneuraminic Acid An N-acyl derivative of neuraminic acid. N-acetylneuraminic acid occurs in many polysaccharides, glycoproteins, and glycolipids in animals and bacteria. (From Dorland, 28th ed, p1518) Sialic Acid,Acid, N-Acetylneuraminic,Acid, Sialic,N Acetylneuraminic Acid
D019267 Hemagglutinin Glycoproteins, Influenza Virus Membrane glycoproteins from influenza viruses which are involved in hemagglutination, virus attachment, and envelope fusion. Fourteen distinct subtypes of HA glycoproteins and nine of NA glycoproteins have been identified from INFLUENZA A VIRUS; no subtypes have been identified for Influenza B or Influenza C viruses.

Related Publications

Logan Kaler, and Ethan Iverson, and Shahed Bader, and Daniel Song, and Margaret A Scull, and Gregg A Duncan
September 1995, The American journal of physiology,
Logan Kaler, and Ethan Iverson, and Shahed Bader, and Daniel Song, and Margaret A Scull, and Gregg A Duncan
January 2014, PloS one,
Logan Kaler, and Ethan Iverson, and Shahed Bader, and Daniel Song, and Margaret A Scull, and Gregg A Duncan
December 2004, The Journal of chemical physics,
Logan Kaler, and Ethan Iverson, and Shahed Bader, and Daniel Song, and Margaret A Scull, and Gregg A Duncan
February 2009, Advanced drug delivery reviews,
Logan Kaler, and Ethan Iverson, and Shahed Bader, and Daniel Song, and Margaret A Scull, and Gregg A Duncan
January 1992, Experientia,
Logan Kaler, and Ethan Iverson, and Shahed Bader, and Daniel Song, and Margaret A Scull, and Gregg A Duncan
October 2021, Physical review. E,
Logan Kaler, and Ethan Iverson, and Shahed Bader, and Daniel Song, and Margaret A Scull, and Gregg A Duncan
July 1990, The Journal of pharmacy and pharmacology,
Logan Kaler, and Ethan Iverson, and Shahed Bader, and Daniel Song, and Margaret A Scull, and Gregg A Duncan
October 2014, Advanced materials (Deerfield Beach, Fla.),
Logan Kaler, and Ethan Iverson, and Shahed Bader, and Daniel Song, and Margaret A Scull, and Gregg A Duncan
January 1987, Biorheology,
Logan Kaler, and Ethan Iverson, and Shahed Bader, and Daniel Song, and Margaret A Scull, and Gregg A Duncan
January 1958, Acta virologica,
Copied contents to your clipboard!